Bristol-Myers Squibb Company (NYSE:BMY) Q4 2025 Earnings call February 05, 2026 08:00 AM ET Company ParticipantsAdam Lenkowsky - Executive Vice President and Chief Commercial OfficerAsad Haider - Managing DirectorChris Boerner - Board Chair and CEOChris Schott - Managing DirectorChuck Triano - Senior Vice President and Head of Investor RelationsCristian Massacesi - Executive Vice President, Chief Medical Officer, and Head of DevelopmentDavid Elkins - EVP and CFODavid Risinger - Senior Managing DirectorGeoff ...

Summary of Bristol-Myers Squibb Company (NYSE:BMY) FY Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (BMY) - **Event**: 44th Annual JPMorgan Healthcare Conference - **Date**: January 12, 2026 Core Industry Insights - **Focus**: The company aims to build a financially strong organization capable of delivering sustainable growth into the 2030s and beyond [2][16] - **Growth Portfolio**: Increased by 17% in the first nine months of 2025, with four products each generating over $1 billion in annual sales [3][2] - **Key Products**: - Opdualag (melanoma) - Breyanzi (CAR-T therapy for lymphoma) - Camzyos (treatment for obstructive HCM) - Reblozyl (annualizing over $2 billion in sales) [3][2] Financial Performance - **Debt Management**: Achieved a $10 billion debt paydown ahead of schedule, resulting in a stronger balance sheet [5][4] - **Cost Optimization**: On track to deliver $2 billion in cost savings, enhancing financial discipline [4][18] - **Shareholder Returns**: Returned over $22 billion to shareholders in the last three years and increased dividends for 17 consecutive years [15][16] Pipeline and R&D Developments - **Pipeline Progress**: Significant advancements in the pipeline with multiple late-stage assets expected to deliver value [5][11] - **Key Late-Stage Assets**: - **Cobenfy**: Approved for schizophrenia; pivotal studies in Alzheimer's disease psychosis expected to read out this year [6][11] - **Milvexian**: A Factor XIa inhibitor with potential in atrial fibrillation and secondary stroke prevention; phase III results anticipated [6][11] - **Admilparant**: Targeting pulmonary fibrosis with phase III results expected [7][11] - **Iberdomide and Mezigdomide**: Oral CELMoDs in multiple myeloma, with promising data leading into phase III trials [9][11] Strategic Focus Areas - **Business Development**: Completed $30 billion in deals over the past 24 months, with a focus on enhancing the growth profile [16][26] - **Execution and R&D**: Emphasis on improving execution across the organization, leveraging AI and machine learning to enhance R&D efficiency [13][30] - **Therapeutic Areas**: Continued focus on building depth in core therapeutic areas while exploring opportunities in adjacent markets [27][28] Market Position and Competitive Landscape - **Confidence in Product Portfolio**: Strong confidence in the existing product portfolio, with Eliquis continuing to perform well despite patent expirations [21][22] - **Diversified Pipeline**: The company has a diversified set of assets, reducing reliance on any single product for growth [23][24] - **Regulatory Engagement**: Positive engagement with the administration regarding Medicaid and pricing strategies, aiming to simplify the healthcare ecosystem [49][50] Conclusion - **Outlook for 2026**: The company is positioned for a busy year with multiple data readouts and product launches expected, focusing on commercial execution and maintaining financial discipline [47][48] - **Long-Term Vision**: Aiming for sustained growth through a diversified portfolio and strategic investments in R&D and business development [12][16]